A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist

[1]  D. Nutt,et al.  Pharmacology of saccadic eye movements in man , 1991, Psychopharmacology.

[2]  Alan Bateson Pagoclone Indevus. , 2003, Current opinion in investigational drugs.

[3]  D. Nutt,et al.  Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder , 2001, Journal of psychopharmacology.

[4]  V J Cunningham,et al.  Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. , 1998, Archives of general psychiatry.

[5]  D. Nutt,et al.  Benzodiazepine Site Pharmacokinetic/Pharmacodynamic Quantification in Man: Direct Measurement of Drug Occupancy and Effects on the Human Brain In Vivo , 1996, Neuropharmacology.

[6]  J. Baron,et al.  Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. , 1996, European journal of pharmacology.

[7]  J. Stutzmann,et al.  RP 59037 and RP 60503: anxiolytic cyclopyrrolone derivatives with low sedative potential. interaction with the gamma-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent. , 1993, The Journal of pharmacology and experimental therapeutics.

[8]  E. Sybirska,et al.  [123I]Iomazenil spect imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain , 1993, Neuropharmacology.

[9]  W. Haefely,et al.  Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. , 1992, The Journal of pharmacology and experimental therapeutics.

[10]  D. Nutt,et al.  Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. , 1991, Psychopharmacology.